IN8bio, Inc. (NASDAQ:INAB – Get Free Report) saw a large decrease in short interest in the month of October. As of October 30th, there was short interest totaling 15,733 shares, a decrease of 52.0% from the October 15th total of 32,797 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average trading volume of 36,207 shares, the short-interest ratio is presently 0.4 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IN8bio in a report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.
Read Our Latest Stock Report on INAB
IN8bio Stock Performance
Shares of INAB stock traded down $0.00 during trading on Monday, hitting $0.82. 5,052,579 shares of the company were exchanged, compared to its average volume of 35,660. IN8bio has a twelve month low of $0.72 and a twelve month high of $2.73. The business’s 50-day simple moving average is $1.10 and its 200 day simple moving average is $1.38. The firm has a market capitalization of $8.82 million, a price-to-earnings ratio of -0.81 and a beta of 0.27.
IN8bio (NASDAQ:INAB – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.10. On average, equities analysts forecast that IN8bio will post -1.49 earnings per share for the current fiscal year.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing ?? T cell therapeutic and ?? T cell engager (TCE) product candidates to address unmet medical needs. ?? T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic ?? T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation.
See Also
- Five stocks we like better than IN8bio
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.
